重大事项：
开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组
科济药业-B(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果
石四药集团(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药
康希诺生物(06185)：曼海欣®获得印度尼西亚注册证书
威胜控股(03393)附属公司中标南方电网招标项目
石药集团(01093)：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准
华检医疗(01931)拟投资人工智能液冷解决方案公司 并申请美国场外交易市场跨境交易
贵州银行(06199)拟收购铜仁丰源80%的股份并将其改建为支行
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.